Pathway-based subnetworks enable cross-disease biomarker discovery
Accurate and actionable biomarkers that integrate diverse molecular, functional and clinical information hold great promise in precision medicine. Here, the authors develop SIMMS, a method for pathway-based cross-disease biomarker discovery.
Guardado en:
Autores principales: | Syed Haider, Cindy Q. Yao, Vicky S. Sabine, Michal Grzadkowski, Vincent Stimper, Maud H. W. Starmans, Jianxin Wang, Francis Nguyen, Nathalie C. Moon, Xihui Lin, Camilla Drake, Cheryl A. Crozier, Cassandra L. Brookes, Cornelis J. H. van de Velde, Annette Hasenburg, Dirk G. Kieback, Christos J. Markopoulos, Luc Y. Dirix, Caroline Seynaeve, Daniel W. Rea, Arek Kasprzyk, Philippe Lambin, Pietro Lio’, John M. S. Bartlett, Paul C. Boutros |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bcb37461217c4cbca56503d084f11052 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
por: Jane Bayani, et al.
Publicado: (2017) -
Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study
por: John M. S. Bartlett, et al.
Publicado: (2021) -
Identification of significantly mutated subnetworks in the breast cancer genome
por: Rasif Ajwad, et al.
Publicado: (2021) -
Astrocytes integrate and drive action potential firing in inhibitory subnetworks
por: Tara Deemyad, et al.
Publicado: (2018) -
Drug repositioning by merging active subnetworks validated in cancer and COVID-19
por: Marta Lucchetta, et al.
Publicado: (2021)